Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 13/20 | 0.53 |
| ▸ | SCN5A | Q14524 | 8/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.51 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.50 |
| ▸ | KCNA5 | P22460 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3754225 | 0.92 | SCN9A (0.54) | SCN9ASCN5AKCNH2P2RX7KCNA5 | |
| SCHEMBL3754837 | 0.90 | P2RX7 (0.47) | SCN9ASCN5AKCNH2P2RX7KCNA5 | |
| SCHEMBL3753653 | 0.89 | LMNA (0.48) | SCN9ASCN5AKCNH2P2RX7KCNA5 | |
| SCHEMBL3758315 | 0.87 | P2RX7 (0.55) | SCN9ASCN5AKCNH2P2RX7KCNA5 | |
| SCHEMBL3753475 | 0.85 | TDP1 (0.54) | SCN9ASCN5AKCNH2P2RX7KCNA5 | |
| SCHEMBL3754236 | 0.85 | SCN9A (0.55) | SCN9ASCN5AKCNH2KCNA5TDP1 | |
| SCHEMBL3756919 | 0.83 | P2RX7 (0.52) | SCN9ASCN5AKCNH2P2RX7KCNA5 | |
| SCHEMBL3757757 | 0.82 | KCNA5 (0.52) | SCN9ASCN5AKCNH2P2RX7KCNA5 | |
| SCHEMBL3750814 | 0.82 | SCN9A (0.66) | SCN9ASCN5AKCNH2KCNA5 | |
| SCHEMBL3762607 | 0.81 | SCN9A (0.53) | SCN9ASCN5AKCNH2P2RX7TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2049484-A1 | ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS | AstraZeneca AB (SE) | 2009-04-22 | — | — | EP | claimed |
| WO-2008008022-A1 | ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2008-01-17 | — | — | WO | claimed |
| US-20080015237-A1 | NEW COMPOUNDS I/418 | ASTRAZENECA AB (SE) | 2008-01-17 | — | — | US | claimed |
| US-20100298392-A1 | Isoindoline Derivatives For The Treatment Of Arrhythmias | ASTRAZENECA AB (SE) | 2010-11-25 | — | — | US | disclosed |
| EP-2049484-A1 | ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS | AstraZeneca AB (SE) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008008022-A1 | ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2008-01-17 | — | — | WO | disclosed |
| US-20080015237-A1 | NEW COMPOUNDS I/418 | ASTRAZENECA AB (SE) | 2008-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015237-A1 | NEW COMPOUNDS I/418 | KCNH1, KCNH2, KCNH3 | SCN9A 119/4885SCN5A 48/4885KCNH2 2/4885 |
| US-20100298392-A1 | Isoindoline Derivatives For The Treatment Of Arrhythmias | KCNH1, KCNH2, KCNQ2 | SCN9A 177/4885SCN5A 26/4885KCNH2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.